Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUC16ecto-targeted CAR T Cells in Recurrent MUC16ecto+ Solid Tumors
NCT02498912Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2015
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 4H11-28z + fIL-12 in ovarian cancer, primary peritoneal carcinoma (PPC) and fallopian tube carcinoma (PFTC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Aug 2015; status: active, not recruiting.
02
Drugs
4H11-28z + fIL-12
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube carcinoma (PFTC)
Beyond the preview
Go deeper on NCT02498912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02498912.